For sale in US market
Morepen Laboratories announced that USFDA has cleared Montelukast Sodium, a bulk drug/ API manufactured by Morepen Laboratories for sale in the US market. This gives Morepen an entry into the Rs 2000 crore (approx. $300 million) US market for Montelukast. The first commercial order for the bulk drug are expected in Q2 of FY 2018-19.Powered by Capital Market - Live News
Disclaimer: No Business Standard Journalist was involved in creation of this content
